Diagnosing Dx

Elevra Consulting
  • 0,0 (0)
  • Life Science
  • Varje vecka

How do we transform cutting-edge scientific discoveries into life-saving diagnostics? On Diagnosing Dx, we explore the scientific innovation driving diagnostics forward, unpack industry challenges, and spotlight success stories. Join us as we speak with leading researchers and innovators at the forefront of Dx. Learn to: 🔹 Navigate industry challenges 🔹 Understand emerging science 🔹 Strategise for growth 🔹 Gain future-focused insight Essential listening for everyone involved in bringing new sciences to life in the Dx and Omics industry, Subscribe now!

  1. What If We Could Test Depression Drugs Before Patients Take Them? Dr Talia Cohen Solal - NeuroKaire

    −3 d

    What If We Could Test Depression Drugs Before Patients Take Them? Dr Talia Cohen Solal - NeuroKaire

    In this episode of Diagnosing Dx, David Filby is joined by Talia Cohen Solal, CEO at NeuroKaire. Talia is a neuroscientist by training who spent more than a decade in academia, including time at Oxford, UCL, and Columbia, before moving into the startup world to get closer to real patient impact. In this conversation, we explore why precision medicine has transformed fields like oncology but still has so far to go in psychiatry, and how NeuroKaire is trying to change that. We discuss the limits of current antidepressant prescribing and how NeuroKaire is using patient-derived neurons to predict which treatments are most likely to work for each individual. This is a practical conversation about precision psychiatry, commercialization, clinical evidence, and what it takes to bring better mental health diagnostics into real patient care. Key takeaways: 🔹 Why psychiatry still lacks the precision medicine approach seen in other fields 🔹 How NeuroKaire is using patient-derived neurons to guide antidepressant treatment 🔹 Why clinical trials and guideline change are essential for real adoption 🔹 How the company is balancing commercial growth with platform expansion and pharma partnerships 🔹 What the future could look like for diagnostics in depression, anxiety, ADHD, and beyond Guest: Talia Cohen Solal CEO at NeuroKaire LinkedIn: https://www.linkedin.com/in/talia-cohen-solal-5b49a78/ Host: David Filby Founder and CEO of Elevra Consulting LinkedIn: https://www.linkedin.com/in/davidfilby/ Chapters: 00:00 Introduction to Talia Cohen Solal and her background 08:23 Transitioning from academia to startups 09:52 The vision behind NeuroKaire and precision psychiatry 12:38 Clinical trials and validation of NeuroKaire’s technology 14:37 Commercialization, distribution, and reimbursement 16:46 Education and awareness in the medical community 19:44 Future growth, market potential, and new indications 26:47 Outlook on diagnostics and the future of neurodiagnostics 🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.

    29 min
  2. Why AI Multiomics Will Replace Ultrasound in Liver Cancer Screening with Bharat Tewarie

    30 juni

    Why AI Multiomics Will Replace Ultrasound in Liver Cancer Screening with Bharat Tewarie

    In this episode of Diagnosing Dx, David Filby is joined by Bharat Tewarie, MD, MBA, CEO at Helio Genomics.   Bharat has led Helio Genomics since July 2025, bringing decades of global healthcare leadership across pharma, biotech, diagnostics, and digital health. In this conversation, we explore why liver cancer surveillance still relies too heavily on outdated imaging, why so many high-risk patients fall through the cracks, and how Helio Genomics is trying to change that with HelioLiver, its blood-based test designed to improve early detection.   We discuss the limitations of ultrasound in liver cancer screening, the promise of AI-powered multiomics, and why early detection only matters if patients can actually access it. Bharat also shares how his clinical and commercial background shapes Helio’s strategy, from workflow design and physician adoption to partnerships, awareness, and the infrastructure needed to move from scientific validation to real clinical impact.   This is a practical conversation about liver cancer, access, commercialization, and what it takes to turn better diagnostics into better outcomes.   Key takeaways:   🔹 Why liver cancer surveillance still leaves too many high-risk patients undetected 🔹 How AI-powered multiomics and HelioLiver could improve early liver cancer detection 🔹 Why access and workflow matter just as much as scientific performance 🔹 How partnerships can accelerate commercialization and patient reach 🔹 What Helio Genomics is building beyond HelioLiver as it expands its platform   Guest: Bharat Tewarie, MD, MBA CEO at Helio Genomics LinkedIn: https://www.linkedin.com/in/bharattewarie/   Host: David Filby Founder and CEO of Elevra Consulting LinkedIn: https://www.linkedin.com/in/davidfilby/ Chapters: 00:00 Introduction to Bharat Tewarie and Helio Genomics 01:42 Bharat’s journey from medicine to business 06:25 The evolution of diagnostics, omics, and AI 10:36 Helio Genomics’ mission and differentiators 12:03 Unmet needs in liver cancer surveillance 14:01 Awareness, access, and clinical workflow challenges 19:10 The role of partnerships in commercialization 26:27 Growth strategy and the future of diagnostics   🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.

    31 min
  3. Start with Reimbursement and Work Backwards - Jonathan Romanowsky

    17 juni

    Start with Reimbursement and Work Backwards - Jonathan Romanowsky

    In this episode of Diagnosing Dx, I’m joined by Jonathan Romanowsky, co-founder of Inflammatix and Principal at Kadima Spark.Jonathan shares lessons from leading diagnostics launches at CareDx, CardioDX, Veracyte, and Inflammatix. We discuss commercialization, reimbursement, fundraising, and why startups need to think about market adoption much earlier than before.We also explore Inflammatix’s evolution into a full IVD company and the key factors that separate diagnostics companies that launch from those that successfully scale.Key takeaways:🔹 Why reimbursement strategy needs to shape diagnostics planning from the start🔹 What makes a launch succeed beyond strong science and clinical validation🔹 Why early-stage companies now need commercial credibility much sooner🔹 How Inflammatix evolved from a molecular signature company into an IVD platform business🔹 What diagnostics founders need to understand about scale, systems, and adoption in 2026Chapters:01:28 Jonathan Romanowsky’s background and career in diagnostics06:20 Why he launched Kadima Spark and what companies need most today11:46 How fundraising pressure is changing commercial strategy22:00 The origin story of Inflammatix29:16 Building a platform company and preparing for launch33:23 Why some diagnostics launches succeed and others fail41:44 How early adoption really works inside health systems44:32 Jonathan’s outlook on the diagnostics market in 2026Guest: Jonathan RomanowskyMedical technology commercialization expert, co-founder of Inflammatix, and Principal at Kadima SparkLinkedIn: https://www.linkedin.com/in/jonathan-romanowsky-6a122/Host: David FilbyFounder and CEO of Elevra ConsultingLinkedIn: https://www.linkedin.com/in/davidfilby/🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.#Diagnostics #Commercialization #Inflammatix #MedicalTechnology #IVD #Biotech #HealthTech #Reimbursement #ProductMarketFit #Fundraising #GoToMarket #ClinicalAdoption #Veracyte #CareDx #DiagnosingDx

    46 min
  4. Start with Reimbursement and Work Backwards - Jonathan Romanowsky

    16 juni

    Start with Reimbursement and Work Backwards - Jonathan Romanowsky

    In this episode of Diagnosing Dx, I’m joined by Jonathan Romanowsky, co-founder of Inflammatix and Principal at Kadima Spark. Jonathan shares lessons from leading diagnostics launches at CareDx, CardioDx, Veracyte, and Inflammatix. We discuss commercialization, reimbursement, fundraising, and why startups need to think about market adoption much earlier than before. We also explore Inflammatix’s evolution into a full IVD company and the key factors that separate diagnostics companies that launch from those that successfully scale. Key takeaways: 🔹 Why reimbursement strategy needs to shape diagnostics planning from the start 🔹 What makes a launch succeed beyond strong science and clinical validation 🔹 Why early-stage companies now need commercial credibility much sooner 🔹 How Inflammatix evolved from a molecular signature company into an IVD platform business 🔹 What diagnostics founders need to understand about scale, systems, and adoption in 2026 Chapters: 01:28 Jonathan Romanowsky’s background and career in diagnostics 06:20 Why he launched Kadima Spark and what companies need most today 11:46 How fundraising pressure is changing commercial strategy 22:00 The origin story of Inflammatix 29:16 Building a platform company and preparing for launch 33:23 Why some diagnostics launches succeed and others fail 41:44 How early adoption really works inside health systems 44:32 Jonathan’s outlook on the diagnostics market in 2026 Guest: Jonathan Romanowsky Medical technology commercialization expert, co-founder of Inflammatix, and Principal at Kadima Spark LinkedIn: https://www.linkedin.com/in/jonathan-romanowsky-6a122/ Host: David Filby Founder and CEO of Elevra Consulting LinkedIn: https://www.linkedin.com/in/davidfilby/ 🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.

    46 min
  5. The EU Market Access Playbook for Diagnostics Companies - Svetlana Nikic

    28 maj

    The EU Market Access Playbook for Diagnostics Companies - Svetlana Nikic

    In this episode of Diagnosing Dx, I’m joined by Svetlana Nikic, Founder of Precision Oncology Consulting.Svetlana shares her journey from Roche and Illumina into building her own consultancy focused on helping diagnostics companies navigate the realities of market access in Europe. We explore the gap between innovation and implementation, why strong science alone does not guarantee patient access, and what US diagnostics companies often underestimate when they look at Europe as a commercial opportunity.We also discuss what it really takes to make oncology diagnostics work across European markets, from KOL engagement and clinical utility studies to health economics, reimbursement strategy, and the complexity of regional healthcare systems. This is a practical conversation about precision oncology, policy, and why implementation may now matter more than innovation.Key takeaways:🔹 Why innovation without implementation does not create real patient impact🔹 What diagnostics companies need to understand before entering Europe🔹 Why clinical utility alone is often not enough for reimbursement in European markets🔹 How KOL engagement, local evidence, and health economics shape adoption🔹 Why diagnostics now needs more implementation focus and less innovation for innovation’s sakeGuest:Svetlana NikicLinkedIn: https://www.linkedin.com/in/svetlananikic/Host:David FilbyLinkedIn: https://www.linkedin.com/in/davidfilby/Chapters:01:50 Svetlana Nikic’s background in diagnostics and oncology07:37 What Precision Oncology Consulting helps companies do in Europe10:25 When diagnostics companies should start planning for Europe15:23 How reimbursement works across European markets19:22 Why KOL engagement is so important for market access20:57 Choosing the right European market and identifying low-hanging fruit25:28 Why the reimbursement bar is often higher in Europe43:30 Diagnostics in 2026: implementation, policy, and what needs to change next🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.#PrecisionOncology #Diagnostics #MarketAccess #Reimbursement #Europe #Oncology #BiomarkerTesting #healthcarepolicy #ClinicalUtility #HealthEconomics #CancerDiagnostics #LifeSciences #HealthCare #PrecisionMedicine #Innovation

    46 min
  6. The EU Market Access Playbook for Diagnostics Companies - Svetlana Nikic

    27 maj

    The EU Market Access Playbook for Diagnostics Companies - Svetlana Nikic

    In this episode of Diagnosing Dx, I’m joined by Svetlana Nikic, Founder of Precision Oncology Consulting. Svetlana shares her journey from Roche and Illumina into building her own consultancy focused on helping diagnostics companies navigate the realities of market access in Europe. We explore the gap between innovation and implementation, why strong science alone does not guarantee patient access, and what US diagnostics companies often underestimate when they look at Europe as a commercial opportunity. We also discuss what it really takes to make oncology diagnostics work across European markets, from KOL engagement and clinical utility studies to health economics, reimbursement strategy, and the complexity of regional healthcare systems. This is a practical conversation about precision oncology, policy, and why implementation may now matter more than innovation. Key takeaways: 🔹 Why innovation without implementation does not create real patient impact 🔹 What diagnostics companies need to understand before entering Europe 🔹 Why clinical utility alone is often not enough for reimbursement in European markets 🔹 How KOL engagement, local evidence, and health economics shape adoption 🔹 Why diagnostics now needs more implementation focus and less innovation for innovation’s sake Chapters: 01:50 Svetlana Nikic’s background in diagnostics and oncology 07:37 What Precision Oncology Consulting helps companies do in Europe 10:25 When diagnostics companies should start planning for Europe 15:23 How reimbursement works across European markets 19:22 Why KOL engagement is so important for market access 20:57 Choosing the right European market and identifying low-hanging fruit 25:28 Why the reimbursement bar is often higher in Europe 43:30 Diagnostics in 2026: implementation, policy, and what needs to change next 🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.

    46 min
  7. The Future of Kidney Transplant Monitoring: Moving Beyond Biopsies - Sara Barrington, CEO of Verici Dx

    19 maj

    The Future of Kidney Transplant Monitoring: Moving Beyond Biopsies - Sara Barrington, CEO of Verici Dx

    In this episode of Diagnosing Dx, I’m joined by Sara Barrington, CEO at Verici Dx. Sara explains how Verici Dx is tackling one of the biggest unresolved problems in kidney transplant care: helping clinicians monitor patients more precisely after transplant without relying so heavily on biopsies and legacy testing. We explore why balancing rejection risk against unnecessary immunosuppression is so difficult, and how better molecular insight could support earlier, more accurate decisions. We also discuss Verici Dx’s RNA sequencing and AI-driven approach, the decision to license one test to Thermo Fisher while commercialising another directly, and what it means to build a diagnostics company that went public from day one. This is a practical conversation about transplant medicine, commercialization, and better clinical decision-making. Key takeaways: 🔹 Why post-transplant monitoring still relies too heavily on invasive and outdated methods 🔹 How RNA sequencing and AI could improve rejection prediction and patient management 🔹 Why reducing unnecessary immunosuppression is such an important clinical goal 🔹 How Verici Dx built an end-to-end transplant testing strategy across pre- and post-transplant care 🔹 What licensing, reimbursement, and public-market strategy look like in a real diagnostics company Guest: Sara Barrington CEO at Verici Dx LinkedIn: https://www.linkedin.com/in/sara-barrington-06926382/ Host: David Filby LinkedIn: https://www.linkedin.com/in/davidfilby/ 🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.

    45 min
  8. The Future of Kidney Transplant Monitoring: Moving Beyond Biopsies - Sara Barrington, CEO of Verici Dx

    18 maj

    The Future of Kidney Transplant Monitoring: Moving Beyond Biopsies - Sara Barrington, CEO of Verici Dx

    In this episode of Diagnosing Dx, I’m joined by Sara Barrington, CEO at Verici Dx. Sara explains how Verici Dx is tackling one of the biggest unresolved problems in kidney transplant care: helping clinicians monitor patients more precisely after transplant without relying so heavily on biopsies and legacy testing. We explore why balancing rejection risk against unnecessary immunosuppression is so difficult, and how better molecular insight could support earlier, more accurate decisions. We also discuss Verici Dx’s RNA sequencing and AI-driven approach, the decision to license one test to Thermo Fisher while commercialising another directly, and what it means to build a diagnostics company that went public from day one. This is a practical conversation about transplant medicine, commercialization, and better clinical decision-making. Key takeaways: 🔹 Why post-transplant monitoring still relies too heavily on invasive and outdated methods 🔹 How RNA sequencing and AI could improve rejection prediction and patient management 🔹 Why reducing unnecessary immunosuppression is such an important clinical goal 🔹 How Verici Dx built an end-to-end transplant testing strategy across pre- and post-transplant care 🔹 What licensing, reimbursement, and public-market strategy look like in a real diagnostics company Guest: Sara Barrington CEO at Verici Dx LinkedIn: https://www.linkedin.com/in/sara-barrington-06926382/ Host: David Filby LinkedIn: https://www.linkedin.com/in/davidfilby/ 🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.

    45 min
Visa alla (90)

Om

How do we transform cutting-edge scientific discoveries into life-saving diagnostics? On Diagnosing Dx, we explore the scientific innovation driving diagnostics forward, unpack industry challenges, and spotlight success stories. Join us as we speak with leading researchers and innovators at the forefront of Dx. Learn to: 🔹 Navigate industry challenges 🔹 Understand emerging science 🔹 Strategise for growth 🔹 Gain future-focused insight Essential listening for everyone involved in bringing new sciences to life in the Dx and Omics industry, Subscribe now!

Information

  • Skapad av
    Elevra Consulting
  • Aktiva år
    2025 - 2026
  • Avsnitt
    90
  • Åldersgräns
    Barnvänligt
  • Copyright
    © 2026 Elevra Consulting
  • Programmets webbplats
    Diagnosing Dx
  • Leverantör